Effect of DHA on Proinflammatory Cytokines Including Platelets Activating Factor (PAF) in Preterm Neonates
Neonatal Disease
About this trial
This is an interventional diagnostic trial for Neonatal Disease
Eligibility Criteria
Inclusion Criteria:
- Preterm neonates having a gestational age equal or less than 32 weeks at birth, admitted in Ain Shams University NICU'S.
Weight (less than or equal 1.500 KG) Clinically stable to begin enteral feeding All Genders (Male, Female) Written informed consent by parents Sepsis will not be considered as exclusion criteria (according to SNAP 11; this score considers six physiologic variables such as blood pressure, temperature, the Po2/Fio2 ratio, serum PH, seizures and urine output, Töllner score (table 3) and Rodwell score
Exclusion Criteria:
- Persistent bleeding at any level. Receiving medication to avoid coagulation. Persistent vomiting. Gastrointestinal malformations. Mother taking Omega-3 supplements and planning to breastfed.
Sites / Locations
- Ain Shams University
Arms of the Study
Arm 1
Arm 2
Other
Other
Group A
Group B
(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.